Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience

References

• Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8:475–87.
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012;380:2018–27.
   PubMed Web of Science ®Google Scholar
• Ost P, Lumen N, Goessaert AS, Fonteyne V, De Troyer B, Jacobs F, et al. High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. Eur Urol 2011;60:842–9.
   PubMed Web of Science ®Google Scholar
• Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009;74:1405–18.
   PubMed Web of Science ®Google Scholar
• Valdagni R, Kattan M, Rancati T, Yu C, Vavassori V, Fellin G, et al. Is it time to tailor the prediction of radio-induced toxicity in prostate cancer? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys 2012;82:1957–66.
   PubMed Web of Science ®Google Scholar
• Barnett GC, De Meerleer G, Gulliford SL, Sydes MR, Elliott RM, Dearnaley DP. The impact of clinical factors on the development of late radiation toxicity: Results from the Medical Research Council RT01 trial (ISRCTN47772397). Clin Oncol (R Coll Radiol) 2011;23:613–24.
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 1999;353:267–72.
   PubMed Web of Science ®Google Scholar
• Fiorino C, Fellin G, Rancati T, Vavassori V, Bianchi C, Borca VC, et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: Preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys 2008;70:1130–7.
   PubMed Web of Science ®Google Scholar
• Gulliford SL, Foo K, Morgan RC, Aird EG, Bidmead AM, Critchley H, et al. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: Evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys 2010;76:747–54.
   PubMed Web of Science ®Google Scholar
• Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010; 76:S10–9.
   PubMed Web of Science ®Google Scholar
• Fonteyne V, De Neve W, Villeirs G, De Wagter C, De Meerleer G. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: The need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol 2007;84: 156–63.
   PubMed Web of Science ®Google Scholar
• De Gersem W, Claus F, De Wagter C, De Neve W. An anatomy-based beam segmentation tool for intesnity-modulated radiation therapy and its application to head-and neck cancer. Int J Radiat Oncol Biol Phys 2001;51:849–59.
   PubMed Web of Science ®Google Scholar
• Fiorino C, Sanguineti G, Cozzarini C, Fellin G, Foppiano F, Menegotti L, et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 2003;57:953–62.
   PubMed Web of Science ®Google Scholar
• Ost P, Speleers B, De Meerleer G, De Neve W, Fonteyne V, Villeirs G et al. Volumetric arc therapy and intensity- modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: A planning comparison study. Int J Radiat Oncol Biol Phys 2011;79:920–6.
   PubMed Web of Science ®Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341–6.
   PubMed Web of Science ®Google Scholar
• Yeoh EE, Fraser RJ, McGowan RE, Botten RJ, Di Matteo AC, Roos DE, et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: Early results of a Phase III randomized trial. Int J Radiat Oncol Biol Phys 2003;55:943–55.
   PubMed Web of Science ®Google Scholar
• Davis KM, Kelly SP, Luta G, Tomko C, Miller AB, Taylor KL. The association of long-term treatment-related side effects with cancer-specific and general quality of life among prostate cancer survivors. Urology 2014;84:300–6.
   PubMed Web of Science ®Google Scholar
• Ghadjar P, Zelefsky MJ, Spratt DE, Munck af Rosenschïld P, Hun Oh J, Hunt M, et al. Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiation Oncol Biol Phys 2014;88:339–44.
   PubMed Web of Science ®Google Scholar
• Pearlstein KA, Chen RC. Comparing dosimetric, morbidity, quality of life and cancer control outcomes after 3D conformal, intensity-modulated and proton radiation therapy for prostate cancer. Semin Radiat Oncol 2013;23:182–90.
   PubMed Web of Science ®Google Scholar
• Goldin GH, Sheets NC, Meyer AM, Kuo TM, Wu Y, Syümer T, et al. Comparative effectivness of intensity- modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy. JAMA Intern Med 2013;173:1136–43.
   PubMed Web of Science ®Google Scholar
• King CR, Kapp DS. Radiotherapy after prostatectomy: Is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys 2008;71:346–50.
   PubMed Web of Science ®Google Scholar
• Spratt D, Pei X, Yamada Y, Kollmeier MA, Cox B, Zelefsky MJ. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2013;85:686–92.
   PubMed Web of Science ®Google Scholar
• Fellin G, Rancati T, Fiorino C, Vavassori V, Antognoni P, Baccolini M, et al. Long term rectal function after high-dose prostate cancer radiotherapy: Results from a prospective cohort study. Radiother Oncol 2014;110:272–7.
   PubMed Web of Science ®Google Scholar
• Krol R, Smeenk RJ, van Lin EN, Yeoh EE, Hopman WP. Systematic review: Anal and rectal changes after radiotherapy for prostate cancer. Int J Colorectal Dis 2014;29:273–83.
   PubMed Web of Science ®Google Scholar
• de Crevoisier R, Tucker SL, Dong L, Mohan R, Cheung R, Cox JD, et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:965–73.
   PubMed Web of Science ®Google Scholar
• Olsson CE, Pettersson N, Alsadius D, Wilderäng U, Tucker SL, Johansson KA, et al. Patient-reported genito-urinary toxicity for long-term prostate cancer survivors treated with radiation therapy. Br J Cancer 2013;108:1964–70.
   PubMed Web of Science ®Google Scholar